#United States #New York #Securities Fraud #Pomerantz LLP #Biogen Inc.

Pomerantz Law Firm Investigates Allegations of Securities Fraud Involving Biogen Inc.

In an urgent development for investors, the Pomerantz Law Firm has launched an investigation into the actions of Biogen Inc., a leading biotechnology company, concerning potential securities fraud. This inquiry follows the company’s recent announcement regarding the results of a key clinical trial, which has raised significant concerns among stakeholders.

The law firm is urging shareholders of Biogen (NASDAQ: BIIB) to come forward and participate in this investigation. Investors may contact Danielle Peyton at Pomerantz LLP to share their experiences or seek guidance on the matter. The inquiry primarily focuses on whether certain officers and/or directors of Biogen have engaged in unlawful or deceptive business practices.

On May 14, 2026, Biogen issued a press release updating the public on the Phase 2 CELIA study results for diranersen (BIIB080), an investigational therapy aimed at addressing early Alzheimer's disease. Although the company described the findings as "compelling," it fell short of achieving its primary dose-response endpoint, which has raised a red flag among investors.

As a result of this news, Biogen's stock price plummeted by 6.43%, closing at $191.37 per share. This sharp decline has caused alarm among investors, prompting the Pomerantz Law Firm's investigation to ensure the rights of the affected parties are protected. The firm is well-regarded in the legal community for its expertise in corporate, securities, and antitrust litigation, and has a strong track record of securing substantial settlements for investors affected by corporate misconduct.

Founded by Abraham L. Pomerantz, known as a pioneer in the field of securities class actions, the firm has spent over 85 years advocating for victims of various forms of financial fraud. Their commitment to defending investors’ rights positions them as a leader in this domain. As part of their ongoing efforts, they have achieved significant damages awards for class members in previous cases, emphasizing their dedication to justice in corporate governance and accountability.

If you are a Biogen shareholder who feels that your investment may have been adversely affected, it is crucial to understand your rights. The Pomerantz Law Firm is encouraging you to reach out for more information about the possibility of joining a class action lawsuit. This legal action could provide restitution for any losses incurred due to the alleged misrepresentations and breaches of fiduciary duty.

For more information, investors are invited to contact Danielle Peyton directly via phone at 646-581-9980, ext. 7980, or through email at [email protected]. The firm is committed to ensuring that no investor is left alone to navigate the complexities of securities litigation.

The investigation reflects Pomerantz’s enduring mission to protect the rights of investors and hold corporations accountable for their actions. In an era where transparency and ethical practices are paramount, this investigation serves as a reminder of the importance of corporate responsibility and investor vigilance.

Stay informed, and take action to protect your rights as an investor in Biogen Inc. as this investigation unfolds. For more insights and updates, visit Pomerantz LLP's website, where you can find valuable resources and information on your rights as a shareholder facing potential securities fraud.